Jared Kaltwasser

Patients who underwent neoadjuvant radiotherapy for soft tissue sarcoma (STS) spent longer in the hospital and were more likely to have wound complications.

Super-enhancer-related microRNAs (miRNAs) reveal diverse subtypes of small cell lung cancer (SCLC), offering potential as diagnostic and prognostic biomarkers.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Polyethylene terephthalate microplastics are the most common microplastics encountered in daily life, and there are several reasons why they may play a role in lung diseases like idiopathic pulmonary fibrosis.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.

The findings could help clinicians individualize infection-prevention strategies in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

The 6-month progression-free survival rate for the combination therapy was 52.2%.

A single-center study comparing patients with chronic lymphocytic leukemia receiving venetoclax as part of a clinical trial and patients receiving it in routine clinical practice showed very high complete response rates in both groups.

Families reported quality of life improvements when they used peanut oral immunotherapy instead of simply avoiding peanuts.

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major risk factors.

As many as one quarter of people with chronic urticaria also have metabolic syndrome, data suggest.

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more comprehensive information is needed to draw strong conclusions.

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery.

Clonally expanded CD8+ T cells appear to play a causal role in the initiation and progression of alopecia areata.

Investigators believe the SWIFT-seq system holds potential to replace more invasive bone marrow biopsies.

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly.

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with healthy controls.

Patients with alopecia universalis and alopecia totalis are at a particularly high risk of cardiovascular disease, a new study has found.

Patients with myeloproliferative neoplasms (MPNs) appear to be at a higher risk of heart failure and pulmonary hypertension, though more research into the links is needed.

Telomere length can be used in the diagnosis of interstitial lung diseases like idiopathic pulmonary fibrosis, but it likely also has therapeutic implications, according to a new report.

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Both systemic sclerosis and systemic lupus erythematosus have down-regulated RGS5, but they also have distinctive genetic expression profiles.

Early identification of multiple myeloma could help clinicians intervene more swiftly.

The use of retinal images can help investigators noninvasively identify chronic kidney disease and assess patient prognosis.

Patients with idiopathic pulmonary fibrosis are at a higher risk of certain cardiovascular diseases.

The QRISK3 assessment is designed for the general population, but it appears to also have utility in patients with essential thrombosis and polycythemia vera.

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The trial is one of 2 phase 3 studies of upadacitinib in patients with severe alopecia areata.